Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze.

@article{Berger2005SafetyOB,
  title={Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze.},
  author={William E Berger and Paul Y Qaqundah and Kathryn Blake and Jose Rodriguez-Santana and A M Irani and John Xu and Mitchell H. Goldman},
  journal={The Journal of pediatrics},
  year={2005},
  volume={146 1},
  pages={91-5}
}
OBJECTIVE To compare the safety of budesonide inhalation suspension (BIS) with placebo in infants 6 to 12 months of age with mild to moderate persistent asthma or recurrent wheeze. STUDY DESIGN In this multicenter, randomized, double-blinded, parallel-group, placebo-controlled study, 141 patients received 0.5 mg BIS (n = 48), 1.0 mg BIS (n = 44), or placebo (n = 49) once daily for 12 weeks. The primary variable was adrenal function, based on cosyntropin-stimulated plasma cortisol levels… CONTINUE READING